effects of a ct-100 dinamo component on cognitive functioning and mood symptoms

Conditions: Multiple Sclerosis; Mild Cognitive Impairment; Cancer

Summary: ct-100 is a platform that provides an interactive, software based therapeutic component that may be used as part of a multimodal treatment in supplementary or standalone prescription or nonprescription software-based digital therapeutics (pdt/dtx), being developed by click therapeutics, inc.

ct-100 is a platform that provides an interactive, software based therapeutic component (ct-100-001) that may be used as part of a multimodal treatment in future prescription or non-prescription software-based digital therapeutics (pdt/dtx). ct-100-001 contains a class of digital neuro-activation and modulation (dinamo) component. this dinamo component targets key neural systems (including, but not limited to, systems related to cognitive control, sensory-, perceptual-, affective-, pain-, attention-, social-, and self-processing) to optimally improve patients' cognitive and mental health. the ct-100-001 dinamo component is designed to improve cognitive impairments and mood challenges. the purpose of the proposed basket study is to evaluate the initial effects of the ct-100-001, a dinamo component (the study app) on cognitive functioning and related outcomes compared to care-as-usual across several non-dsm-5 indications. these indications have known high prevalence of cognitive impairments due to the illness and/or treatments. such as in multiple sclerosis, breast or lung cancer, and mild cognitive impairment.

Eligibility criteria:
inclusion criteria: a participant will be eligible for entry into the study if all the following criteria are met: 1. age ranges in years: 22-52 for multiple sclerosis, 35-65 for cancer (breast or lung), and 45-75 for mild cognitive impairment. 2. diagnosis of indication under study (multiple sclerosis, cancer - breast or lung, mild cognitive impairment) 3. self-reported cognitive impairment and mood symptoms that began in the context of the primary indication under study. 4. fluent in written and spoken english (confirmed by ability to read and comprehend the informed consent form.) 5. willing and able to comply with study protocol and assessments, evidenced by completion of the screening survey. 6. lives in the united states. 7. has an active email address and is willing and able to receive email messages. 8. is the sole user of an iphone or a smartphone with an android operating system, and with cellular and/or internet access for the duration of the study period. exclusion criteria: a participant is excluded from the study if any of the following criteria apply: 1. physician-diagnosed insomnia in the screening survey. 2. cognitive impairment/mood symptoms or clinical diagnosis of depression attributed to a condition other than the underlying medical condition. 3. is currently pregnant or breastfeeding. 4. substance use disorder within the past 1 year. 5. initiation or change in central nervous system-active medication (e.g., antidepressants) during the last 2 months. 6. participation in a clinical trial within the last 3 months. 7. anticipates a lifestyle change or change in current treatment during the study period that could affect cognitive functioning. 8. visual, dexterity or cognitive deficit so severe that precludes the use of an app. 9. severe neurological disorders impairing brain function. 10. psychiatric hospitalization in the past 6 months.

Keywords: digital therapeutics phone app virtual study